Technology
Health
Medical

Bellerophon Therapeutics

$0.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0237 (-3.86%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BLPH and other stocks, options, ETFs, and crypto commission-free!

About

Bellerophon Therapeutics, Inc. Common Stock, also called Bellerophon Therapeutics, is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Read More The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Employees
17
Headquarters
Warren, New Jersey
Founded
2009
Market Cap
42.29M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
510.67K
High Today
$0.6081
Low Today
$0.5883
Open Price
$0.6081
Volume
84.68K
52 Week High
$3.30
52 Week Low
$0.47

Collections

Technology
Health
Medical
Therapy
2015 IPO
US
North America

News

NasdaqMay 9

Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results

WARREN, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2019. "Bellerophon has achieved substantial progress in the beginning of 2019 with additional important milestones expected later this year," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "We reported positive results ...

282
Yahoo FinanceMay 3

What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes 'a business with enduring competitive advantages that is run by able and owner-oriente...

207
Simply Wall StMay 2

A Spotlight On Bellerophon Therapeutics, Inc.’s (NASDAQ:BLPH) Fundamentals

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) due to its excellent fundamentals in more than one area. BLPH is a company that has been able to sustain great financial health, trading at an attractive share price. Below, I’ve touched on some key aspects you should know on a...

113

Earnings

-$0.44
-$0.30
-$0.15
-$0.01
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.01 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.